Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML
- Status
- TERMINATED
- Phase
- PHASE2
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
- Status
- COMPLETED
- Phase
- PHASE2
5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
- Status
- COMPLETED
- Phase
- PHASE2
Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
- Status
- UNKNOWN
- Phase
- PHASE2
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2